Celularity Acquires Rebound, A Placental-derived Allograft Matrix Product, From Sequence LifeScience; No Terms Disclosed

Benzinga · 10/16 21:21

Robert J. Hariri, Chairman, CEO and founder of Celularity. "We expect Rebound sales to contribute meaningfully in the fourth quarter 2024 and to fulfill expected full year 2024 biomaterial sales which we announced in February, augmenting our other revenues from biobanking and research agreements."